Mission Statement, Vision, & Core Values (2024) of Aadi Bioscience, Inc. (AADI)

An Overview of Aadi Bioscience, Inc. (AADI)

General Summary of Aadi Bioscience, Inc. (AADI)

Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing precision therapies for cancers with alterations in the mTOR pathway. The company was formed following a merger with Aerpio Pharmaceuticals, Inc. on August 26, 2021. Aadi's lead product, FYARRO (sirolimus protein-bound particles for injectable suspension), received FDA approval in November 2021 and was launched in February 2022 for the treatment of advanced malignant perivascular epithelioid cell tumor (PEComa). FYARRO combines nanoparticle albumin-bound technology with the anti-cancer agent sirolimus, targeting a rare cancer indication.

As of 2024, Aadi has recognized net product sales of $18.7 million for the nine months ended September 30, 2024. The company continues to invest in research and development while navigating the complexities of the biopharmaceutical landscape.

Company's Financial Performance in the Latest Financial Reports

In the financial period ending September 30, 2024, Aadi Bioscience reported:

• Total revenue: $18.7 million for the nine months ended September 30, 2024, compared to $18.0 million for the same period in 2023.
• Product sales, net: $7.2 million for the three months ended September 30, 2024, compared to $5.96 million for the same quarter in 2023.
• Operating expenses: Total operating expenses for the nine months ended September 30, 2024, were $67.3 million, compared to $72.2 million for the same period in 2023.
• Net loss: The net loss for the nine months ended September 30, 2024, was $45.4 million, compared to $49.5 million for the same period in 2023.
• Cash and cash equivalents: As of September 30, 2024, Aadi had cash, cash equivalents, and short-term investments totaling $62.6 million.

The company is actively working to achieve profitability, having incurred an accumulated deficit of $314.4 million as of September 30, 2024.

Introduction to Aadi Bioscience as a Leader in the Industry

Aadi Bioscience has established itself as a leading player in the biopharmaceutical industry, particularly in the niche of precision cancer therapies. The company's focus on the mTOR pathway positions it uniquely to address specific cancer types that are underserved by existing therapies. With the successful launch of FYARRO and ongoing clinical trials, Aadi is poised to expand its market presence and enhance its product offerings.

Investors and stakeholders are encouraged to explore further the strategic initiatives that underscore Aadi's commitment to innovation and patient care, as the company continues to navigate the challenges of the biopharmaceutical landscape.

Mission Statement of Aadi Bioscience, Inc. (AADI)

Mission Statement of Aadi Bioscience, Inc. (AADI)

Aadi Bioscience, Inc. (AADI) is dedicated to developing and commercializing precision therapies for cancers characterized by alterations in the mTOR pathway. This commitment is encapsulated in its mission statement, which serves as a guiding principle for the company's long-term objectives and operational strategies. The mission statement emphasizes the company's focus on innovation, patient-centric solutions, and quality in its product offerings.

Core Components of the Mission Statement

1. Innovation in Cancer Treatment

Aadi's mission highlights its dedication to innovation, particularly in the realm of cancer therapeutics. The company's lead product, FYARRO (sirolimus protein-bound particles for injectable suspension), was approved by the FDA in November 2021 for the treatment of advanced malignant perivascular epithelioid cell tumor (PEComa). This innovative therapy combines nanoparticle albumin-bound technology with sirolimus, targeting the mTOR pathway, a critical regulator of cell growth and cancer progression.

2. Commitment to Patient-Centric Solutions

The mission statement underscores Aadi's commitment to delivering patient-centric solutions. This commitment is reflected in the company's ongoing clinical trials and research efforts. For instance, as of September 30, 2024, Aadi has paused new enrollment in Phase 2 trials for advanced endometrioid-type endometrial cancer (EEC) and neuroendocrine tumors (NETs) while continuing to dose previously enrolled patients. This approach ensures that the needs of existing patients are prioritized, even amid strategic shifts in research focus.

3. Quality and Compliance in Operations

Aadi's mission also emphasizes the importance of quality and compliance in its operations. The company has incurred significant expenses related to research and development, totaling $36.7 million for the nine months ended September 30, 2024. These investments are crucial for maintaining high standards in product development and ensuring that all therapies meet regulatory requirements before reaching the market.

As of September 30, 2024, Aadi had an accumulated deficit of $314.4 million, indicating the financial challenges faced as it invests in innovative therapies and navigates the complexities of the biopharmaceutical landscape. The company recognizes that achieving its mission requires not only innovative products but also a steadfast commitment to quality and patient care, which are integral to its long-term success.

Vision Statement of Aadi Bioscience, Inc. (AADI)

Vision Statement of Aadi Bioscience, Inc. (AADI)

Aadi Bioscience, Inc. is committed to developing and commercializing precision therapies that target cancers with alterations in the mTOR pathway. As of 2024, the company emphasizes innovation and patient-centric approaches in its vision statement, focusing on the following key components:

Aadi aims to be at the forefront of developing innovative treatment options. The lead product, FYARRO (sirolimus protein-bound particles for injectable suspension), was approved by the FDA for treating advanced malignant perivascular epithelioid cell tumor (PEComa) in November 2021 and launched commercially in February 2022. For the three and nine months ended September 30, 2024, net product sales of FYARRO were reported at $7.2 million and $18.7 million, respectively.

The company continues to invest in research and development to expand its product pipeline. As of September 30, 2024, Aadi had incurred research and development expenses of approximately $36.7 million for the nine months ended September 30, 2024. This commitment reflects Aadi's strategy to innovate and address unmet medical needs in oncology.

Aadi's vision includes a strong focus on patient outcomes. The company is dedicated to providing therapies that improve the quality of life for patients with rare cancers. Aadi's efforts in clinical trials and product development are centered on delivering effective solutions tailored to patient needs and preferences.

To enhance its capabilities and accelerate growth, Aadi seeks strategic collaborations. The BMS License Agreement is a significant partnership that allows Aadi to leverage Bristol-Myers Squibb's resources and expertise. As of September 30, 2024, Aadi made a payment of $5.8 million to BMS under this agreement.

Aadi's financial health is crucial for sustaining its vision. As of September 30, 2024, the company reported an accumulated deficit of $314.4 million. Despite ongoing net losses, which were $12.5 million for the three months ended September 30, 2024, Aadi maintains a cash position of $62.6 million, which is expected to support operations into the second half of 2026.

Aadi Bioscience, Inc. continues to focus on its vision of transforming cancer treatment through innovation, dedication to patient care, and strategic partnerships, aiming to enhance its market presence and financial stability in 2024 and beyond.

Core Values of Aadi Bioscience, Inc. (AADI)

Integrity

Aadi Bioscience, Inc. emphasizes integrity as a core value, ensuring that all actions and decisions reflect honesty and transparency. This commitment is crucial for building trust with stakeholders, including patients, healthcare providers, and investors.

In 2024, Aadi demonstrated integrity through its transparent communication regarding clinical trial results. Following the decision to halt the PRECISION1 trial, the company promptly disclosed the reasons and implications to its stakeholders, reflecting a commitment to ethical practices in clinical research.

Innovation

Innovation drives Aadi's mission to develop advanced therapies for patients with rare cancers. The company’s focus on innovative solutions is evident in its research and development strategy.

In 2024, Aadi allocated approximately $36.7 million to research and development, showcasing its dedication to advancing its product pipeline. The launch of FYARRO, approved for advanced malignant PEComa, exemplifies Aadi’s commitment to innovation in oncology.

Collaboration

Aadi values collaboration as essential for achieving its goals in biopharmaceutical development. This core value is reflected in its partnerships and teamwork across departments.

The company has collaborated with various stakeholders, including healthcare professionals and research institutions, to enhance the efficacy of its products. For instance, Aadi’s partnership with Fresenius Kabi for the manufacturing of FYARRO emphasizes the importance of collaboration in ensuring product availability.

Excellence

Aadi is committed to excellence in all aspects of its operations, from research and development to customer service. This core value ensures that the company consistently meets high standards.

In 2024, Aadi achieved a net product sales figure of $18.7 million for FYARRO, reflecting its dedication to delivering high-quality products to the market. Additionally, a decrease in operating expenses from $72.2 million in 2023 to $67.3 million in 2024 indicates a focus on operational excellence and efficiency.

Accountability

Accountability is a fundamental value at Aadi, ensuring that the company takes responsibility for its actions and their impact on stakeholders.

In 2024, Aadi reported an accumulated deficit of $314.4 million, which underscores the importance of accountability in managing financial resources and strategic decisions. The company's proactive approach to addressing its financial challenges reflects its commitment to being accountable to its investors and stakeholders.

Updated on 16 Nov 2024

Resources:

1. Aadi Bioscience, Inc. (AADI) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Aadi Bioscience, Inc. (AADI)' financial performance, including balance sheets, income statements, and cash flow statements.
2. SEC Filings – View Aadi Bioscience, Inc. (AADI)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.